An official website of the United States government
) or https:// means you've safely connected to the .mil website. Share sensitive information only on official, secure websites.
Prostate Cancer
Research Highlights/News
2025 | 2023 | 2022 | 2021 | 2020
» Look for consumer stories click here
2025
Research Highlights:
- CDMRP Accelerates Advancements in Cancer Screening for Warfighters, Veterans and the Nation
- CDMRP FUNDS MENTORED SCIENCE TO EXPAND CAPACITY FOR IMPACTFUL PROSTATE CANCER RESEARCH
2024
Press Releases:
2023
Research Highlights:
- Therapeutic Targeting of Neuroendocrine Prostate Cancer
- B7-H3 (CD276) as a Therapeutic Target in Lethal Prostate Cancers
- An International Registry to Inform Treatment Choices for Patients with Advanced Prostate Cancer
- Unique Structural Characterization of Androgen Receptor - A Key Protein in Prostate Cancer
2022
Research Highlights:
- PSMA-PET Imaging in Prostate Cancer: From Detection to Therapeutics
- Neuroendocrine Differentiation and Enzalutamide Resistance in Prostate Cancer
- Quality of Life among African American Prostate Cancer Survivors and Their Partners: A Multilevel Perspective
2021
Research Highlights:
- Combining Nanotechnology and Radiation to Enhance Checkpoint Blockade Immunotherapy of Advanced Prostate Cancer
- The Impact of a Gene Expression Profile on Treatment Choice and Outcome among Minority Men Newly Diagnosed with Prostate Cancer
- Effects of CD24/RCC2/p53 Signaling on Prostate Cancer Metastasis
- Novel Tumor Suppressive Role of Phosphodiesterases in Prostate Cancer
- Alleviating Immunosuppression to Enhance CAR T-Cell Efficacy in Metastatic Prostate Cancer
2020
Research Highlights:
- Identifying Genomic Drivers of Prostate Cancer Progression
- Investigating Racial Differences in the Financial Impact of Prostate Cancer
- Preserving Sexual Function in Men Undergoing Radiation Treatment for Prostate Cancer
- High dose testosterone causes DNA damage and suppresses prostate cancer growth
- Bipolar Androgen Therapy: Breaking Out of the Chrysalis of Chronic Androgen Deprivation Therapy in Men with Late-Stage Castrate-Resistant Prostate Cancer
- BET Bromodomain Degraders for the Treatment of Metastatic Prostate Cancer
- Using a novel genetically engineered mouse model to identify new drug targets for treatment-resistant metastatic prostate cancer
Last updated Friday, October 24, 2025